Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.

Sarah CroessmannLuigi FormisanoLisa N Kinch Paula I Gonzalez EricssonDhivya R SudhanRebecca J NagyAju MathewEric H BernickerMassimo CristofanilliJie HeRichard E CutlerAlshad S LalaniVincent A MillerRichard B LanmanNick V GrishinCarlos L Arteaga

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

ERBB2 mutations hyperactivate the HER3/PI3K/AKT/mTOR axis, leading to antiestrogen resistance in ER+ breast cancer. Dual blockade of the HER2 and ER pathways is required for the treatment of ER+/HER2 mutant breast cancers.

Keyphrases

endoplasmic reticulum
estrogen receptor
breast cancer cells
tyrosine kinase
signaling pathway
replacement therapy